Articles for author: Ron Finklestien

January 8, 2024

Ron Finklestien

Stock Market News: Boeing, American Eagle Outfitters, Harpoon Therapeutics, and More

On the precipice of historic inflation data and upcoming big bank earnings, stock futures found themselves in a precarious position, trading mixed on Monday. But amidst this divergence, there were standout performers and underachievers in the market, with a slew of stocks making significant moves. Here are the key highlights from Monday, January 8, 2024: Best Performing Stocks Ambrx Biopharma (NASDAQ:AMAM) soared by an exorbitant 103% following the announcement of Johnson & Johnson’s acquisition of the biotech firm. This all-cash merger, valuing the company at approximately $2 billion, exemplifies the allure of the pharmaceutical sector. The hesitation about the accounting

January 8, 2024

Ron Finklestien

Sherwin-Williams Company’s Stocks on an Upward Trajectory! Sherwin-Williams Company’s Stocks on an Upward Trajectory!

The Sherwin-Williams Company’s SHW shares have rallied 17.8% in the past three months, modestly outperforming its industry’s growth of 16% over the same period. The company has topped the S&P 500’s roughly 8.8% rise over the same period. Image Source: Zacks Investment Research Let’s take a look at the factors that are driving this Zacks Rank #2 (Buy) stock. Sherwin-Williams is gaining from the strength in its Paint Stores Group division, along with initiatives to reduce costs and increase pricing, as well as expanded operations. The company is growing its retail operations in response to robust domestic demand. Auto refinishing

January 8, 2024

Ron Finklestien

Analysis of Burning Rock’s Potential De-Listing and Privatization Burning Rock Grapples with Potential Delisting and Privatization

Key Takeaways: Burning Rock announced its shares could be delisted due to prolonged trading below the required $1 threshold The cancer detection specialist’s former biggest revenue source tumbled 40.6% in the third quarter amid an industry crackdown, spotlighting a major risk for Chinese companies By Doug Young Its name is Burning Rock Biotech Ltd. BNR, but these days the maker of cancer screening-products might be better named “Burning Cash.” Its dwindling cash pile as the company continues to lose money is weighing heavily on investors’ minds these days, pushing its formerly high-flying stock below the $1 level since Nov. 10, or for

January 8, 2024

Ron Finklestien

Top Stock Picks for 2024 Unlocking the Potential: Top Stock Picks For 2024

In 2023, the stock market made an impressive recovery from one of its worst years in over a decade, which occurred in 2022. However, the journey for us investors hasn’t been smooth. Amid worries about inflation, escalating interest rates, an unforeseen crisis in regional banking, and escalating global tensions such as conflicts in Ukraine and Palestine, the US economy displayed resilience. Corporate profits saw an upward trend despite these challenges. The year 2023 saw impressive returns across indices: S&P 500 posted a return of 24.2%. Dow Jones gained 13.8%. NASDAQ 100 surged by 43.4%. My portfolio yielded a return of

January 8, 2024

Ron Finklestien

Nexus Industrial REIT: A Perfect Blend Of Growth And Yield Nexus Industrial REIT: A Perfect Blend Of Growth And Yield

All figures are in $CAD unless otherwise noted All financial information is from Seeking Alpha unless otherwise noted. Investment Proposition Nexus Industrial REIT (TSX:NXR.UN:CA)(OTC:EFRTF) has shown relentless aggression in the industrial property acquisition market in recent years. This determined focus has not only expanded Nexus’s portfolio but also streamlined its operations, solidifying its status as a pure-play industrial REIT. From an investment standpoint, Nexus offers a compelling opportunity, characterized by promising rental growth that is expected to surpass its peers, along with an appealing relative valuation. The prospect of decreasing interest rates could further bolster Nexus’s growth trajectory. However, investors

January 8, 2024

Ron Finklestien

J.Jill Shows Resilience as ICR Conference Looms J.Jill Shows Resilience as ICR Conference Looms

Photo by Jira Pliankharom J.Jill (NYSE:JILL) demonstrated its confidence by reiterating its previous Q4 and full-year guidance on Monday, just before its crucial presentation and investor meetings at the ICR Conference in Orlando, Florida. For Q4, J.Jill (JILL) expects revenue growth to remain approximately level with the prior year, with adjusted EBITDA projected to range between $11.0M and $13.0M. Throughout the full year, J.Jill (JILL) anticipates adjusted EBITDA to decrease by a small margin compared to the prior year. The Q4 and full-year adjusted EBITDA forecast incorporates an approximate $2.0M benefit from the 53rd week in fiscal 2023. Despite a

January 8, 2024

Ron Finklestien

Beyond The Heart: Cardio Diagnostics’ Revolutionary Platform Beyond The Heart: Cardio Diagnostics’ Revolutionary Platform

Groundbreaking Platform Cardio Diagnostics, a leading artificial intelligence-powered precision cardiovascular medicine company, has introduced an unparalleled platform called Actionable Clinical Intelligence (ACI). This groundbreaking initiative provides innovative epigenetic and genetic insights to clinicians prescribing the company’s Epi+Gen CHD and PrecisionCHD tests. Revolutionizing Cardiac Diagnostics Epi+Gen CHD and PrecisionCHD are powerful tests that predict the risk of coronary heart disease (CHD) events and facilitate the detection of CHD. These AI-powered integrated genetic-epigenetic clinical tests can be conveniently administered through a simple blood draw at home or in provider settings, bypassing the need for prolonged waiting times. Unprecedented Insights The integration of

January 8, 2024

Ron Finklestien

Assessing the Recent Sell-Off and the Future Outlook I Foresaw Last Week’s Selloff, Not The Ferocity. Now, I’m More Bullish

As mentioned in the article from last Sunday, the anticipation for more selling in the recent week was evident. The selling on Friday signaled a continuation of the trend, attributed to tax-motivated profit-taking. Thus, while we braced for the selling, the intensity of the sell-off caught us off guard and has altered the outlook for this quarter. The unexpected fierceness of the sell-off has led to a shift in my stance. Contrary to my sentiment in the previous weeks, I am now more bullish. The market’s failure to break out to an all-time high, where it only reached, but did

January 8, 2024

Ron Finklestien

BlackRock TCP Capital: Merging Into the Big Leagues in the BDC Space

Exploring the Potential Post-Merger For dividend investors, Business Development Companies (BDCs) hold a special place. The aftershocks of the banking crisis in early 2023 are expected to make the sector (BIZD) even more appealing over time. Amid my existing BDC favorites, BlackRock TCP Capital (NASDAQ:TCPC) has captured my attention with its recent merger announcement. This development has spurred a comprehensive analysis to ascertain TCPC’s potential to become a major player in the BDC landscape post-merger. Company Overview BlackRock TCP Capital is a BDC focusing on debt investments in private, middle-market companies with enterprise values typically ranging from $100 million to

January 8, 2024

Ron Finklestien

Five Below backs prior guidance ahead of ICR Conference presentation

Five Below Marches Ahead with Confident Strides A Pivotal Moment jetcityimage/iStock Editorial via Getty Images Five Below (NASDAQ:FIVE) decided to shed light on its financial standing prior to its eagerly anticipated appearance at the ICR Conference in Orlando, Florida this Monday. The bustling retailer unveiled its unyielding confidence in its expectations for the Q4 and full year fiscal 2023 results, assuring stakeholders that the net sales would nestle into the upper echelon of the range and that comparable sales would hover around 3%. Total sales for the holiday period surged upward by an impressive 15.6% to $1.16B, with comparable sales